HEALTHJun 5 · 13:50 UTCQUARTZColleen Cabili

Pfizer is licensing an AI startup's drug discovery software to speed up antibody design

Pfizer is licensing an AI startup's drug discovery software to accelerate antibody design. The software's Chai-3 model doubles the antibody design success rate compared to its predecessor.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

PfizerorganizationChai-3topicdrug discovery softwaretopic

Spot something wrong with this article?Report a problem →

Forward this